Streetbeat News

SVRA

Savara Inc.

https://www.savarapharma.com

Industry

Biotechnology

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Open

2.45

Mkt cap

427M

Volume

978K

High

2.51

P/E Ratio

-5.79

52-wk high

5.70

Low

2.42

Div yield

N/A

52-wk low

2.40

Savara Inc. has announced the grant of inducement awards to five new employees, consisting of options to purchase 97,500 shares of the company's common stock.

Portfolio Pulse from

February 14, 2025 | 9:30 pm

Savara Inc. announced the publication of a manuscript in ERJ Open Research detailing long-term outcomes of molgramostim inhalation solution in treating autoimmune pulmonary alveolar proteinosis (aPAP). The study suggests molgramostim effectively addresses the disease's underlying pathophysiology.

Portfolio Pulse from

January 30, 2025 | 2:00 pm

Savara Inc. has initiated a rolling submission of a Biologics License Application (BLA) to the FDA for MOLBREEVI, a potential treatment for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI has received Fast Track and Breakthrough Therapy Designations.

Portfolio Pulse from

December 18, 2024 | 9:30 pm

Savara Inc. will present encore results from its Phase 3 IMPALA-2 trial of Molgramostim for treating autoimmune pulmonary alveolar proteinosis at the British Thoracic Society Winter Meeting 2024.

Portfolio Pulse from

November 22, 2024 | 1:15 pm

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Savara (NASDAQ:SVRA) and maintained a $10 price target.